Nurix Therapeutics Appoints Arati V. Rao, M.D., as Chief Medical Officer
Key Highlights
- ➤Nurix (NRIX) appoints Arati V. Rao, M.D., as chief medical officer
- ➤Rao will lead clinical development as Nurix advances registrational bexobrutideg program
- ➤Bexobrutideg is co-developed with Roche across oncology and autoimmune disease programs
- ➤Rao brings more than 20 years of hematology, oncology, development and regulatory experience
Expert Statements
Arthur T. Sands, M.D., Ph.D., President and Chief Executive Officer of Nurix Therapeutics
“Arati brings deep expertise in hematologic malignancies and a record of leading global development programs from clinical investigation through regulatory submission and approval”
Arthur T. Sands, M.D., Ph.D., President and Chief Executive Officer of Nurix Therapeutics
“As we advance bexobrutideg with Roche, her experience will be invaluable in executing our clinical strategy.”
Arthur T. Sands, M.D., Ph.D., President and Chief Executive Officer of Nurix Therapeutics
“Arati’s leadership across early- and late-stage development will also help us translate the next generation of Nurix's scientific advances into potential new medicines for patients.”
Arati V. Rao, M.D., Chief Medical Officer of Nurix Therapeutics
“Targeted protein degradation offers a compelling opportunity to develop new treatments for patients whose diseases remain inadequately controlled by existing therapies”
Arati V. Rao, M.D., Chief Medical Officer of Nurix Therapeutics
“Nurix has built a strong scientific foundation and a clinical pipeline with the potential to make a meaningful difference in patients' lives.”
Arati V. Rao, M.D., Chief Medical Officer of Nurix Therapeutics
“I look forward to working with the Nurix team, our partners and clinical investigators to advance bexobrutideg and bring additional programs into and through clinical development.”
BRISBANE, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced the appointment of Arati V. Rao, M.D., as chief medical officer. Dr. Rao brings more than 20 years of experience spanning academic hematology and oncology, early- and late-stage clinical development, and global regulatory submissions. She will lead Nurix's clinical development organization as the company advances its registrational program for bexobrutideg and its broader pipeline.
“Arati brings deep expertise in hematologic malignancies and a record of leading global development programs from clinical investigation through regulatory submission and approval," said Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix. "As we advance bexobrutideg with Roche, her experience will be invaluable in executing our clinical strategy. Arati’s leadership across early- and late-stage development will also help us translate the next generation of Nurix's scientific advances into potential new medicines for patients.”
Get started
Create a free account to read the full story.